For extended-release parenteral depots, 50:50 DL-lactide/glycolide copolymers with acid termination are processed through a water-in-oil-in-water double emulsion followed by solvent extraction/hardening. The B6010-2 grade is typically dissolved in dichloromethane at a polymer concentration of 5–25 wt%, with the exact upper limit dictated by the batch inherent viscosity on the certificate of analysis. A primary emulsion is prepared by combining an internal aqueous phase—commonly 10–25 mM sodium acetate buffer at pH 5.5–6.0 containing the active compound—with the organic phase under rotor-stator shear at 10,000–20,000 rpm for 30–120 seconds. This primary emulsion is then dispersed into a 0.5–2.0 wt% polyvinyl alcohol continuous phase at 5,000–10,000 rpm, producing intermediate droplets. The suspension is transferred to a hardening bath containing 2–5% isopropanol or cold phosphate-buffered water at 4–10°C, where solvent extraction proceeds over 3–5 hours under agitation. Terminal microspheres are collected by sieving or centrifugation, washed, lyophilised, and packaged as a sterile dry powder for reconstitution. The resulting microsphere size typically falls between 20 µm and 100 µm D50, with residual moisture below 1 wt% and residual dichloromethane controlled to USP <467> or ICH Q3C Option 1 limits. Release testing uses USP Apparatus 4 or Apparatus 1 with sink conditions at pH 7.4 and 37°C; sterility and endotoxin testing follow USP <71> and USP <85>, while subvisible particulate matter is assessed under USP <788> and visible particulates under USP <790>. Because the copolymer is acid-terminated, hydrolytic degradation is accelerated relative to ester-capped 50:50 PLGA of equivalent inherent viscosity; mass loss onset in pH 7.4 phosphate-buffered saline at 37°C is generally reported at 4–6 weeks for non-porous films, but porous microsphere depots can release faster due to high surface area. Process failure at the pilot scale is most commonly observed when organic-phase viscosity exceeds approximately 1 Pa·s at 25°C, causing filamentous droplet breakup, bimodal particle distributions, and increased 24-hour burst release. Below 50 mPa·s, encapsulation efficiency falls because the primary emulsion droplets coalesce before the hardening bath.

How Does Acid End-Group Content Shift Nanoprecipitation Windows in Antisolvent Processing?

Nanoprecipitation of 50:50 DL-PLG into carrier-free nanoparticles is governed by antisolvent-to-solvent ratio, solvent-side nonsolvent miscibility, and polymer chain supersaturation. For an acid-terminated polymer such as B6010-2, the free carboxylic acid groups increase hydrophilicity relative to an ester-capped analogue, shifting the solvent/nonsolvent diffusion boundary toward more polar solvent mixtures and lowering the energy barrier to nucleation in aqueous environments. A typical process dissolves the copolymer at 5–15 mg/mL in acetone or acetonitrile, then injects the solution at a controlled flow rate into a 5–20-fold excess of 0.1–1.0 wt% poloxamer 188 or polyvinyl alcohol in water under high-shear mixing at 600–1,200 rpm. For improved batch reproducibility, a confined impingement jet mixer or a microfluidic Y-junction is used so that mixing time is below 3 milliseconds and the polymer supersaturation profile is uniform. The organic solvent is removed under reduced pressure at 25–35°C, yielding a monodisperse nanosuspension. Particle size measured by dynamic light scattering under ISO 22412:2017 typically falls from 80 nm to 200 nm with a polydispersity index below 0.2 when the aqueous-to-organic ratio exceeds 10:1. Terminal processing includes addition of 2–5 wt% trehalose or sucrose as a lyoprotectant, sterile filtration through a 0.22 µm membrane where particle size permits, and lyophilisation. The final container is tested for subvisible particulate matter under USP <788>, sterility under USP <71>, and bacterial endotoxins under USP <85>. Published data for B6010-2 in confined impingement jet mixers specifically is limited; the boundaries above should be confirmed against the batch viscosity and acid number because these two parameters determine precipitation rate more directly than nominal lactide-to-glycolide ratio alone.

In-Situ Depot Formation Requires Viscosity Control Below Filter Membrane Limits

Because the water-miscible carrier N-methyl-2-pyrrolidone (NMP) diffuses rapidly from a precipitated polymer phase, subcutaneous depots formed from 25–45 wt% PLGA solutions develop a high-viscosity core after injection into an aqueous physiological environment. The B6010-2 copolymer is dissolved in NMP at 40–50°C under dry nitrogen, with polymer content adjusted so that the apparent viscosity at 25°C remains below approximately 5 Pa·s for 21G needle injection without pre-warming. Drug loadings between 5 wt% and 20 wt% are common for small molecules, peptides, and certain poorly water-soluble actives. The terminal injectable is either filled as a single-syringe system with 0.45 µm or 0.22 µm membrane filtration during aseptic filling, or terminally sterilised only if the active and polymer degradation data demonstrate that irradiation does not alter molar mass distribution. A critical process conflict is that increasing PLGA concentration above 40 wt% improves depot integrity and slows initial release, but reduces filter throughput and raises injection force. At concentrations below 20 wt%, the depot may fragment or release a high initial fraction within the first 24 hours. In vitro release is generally assessed in phosphate-buffered saline at pH 7.4 and 37°C with a water bath or shaking incubator; local tissue response is evaluated under ISO 10993-6, while systemic endpoints follow ISO 10993-11. Sterility and endotoxin limits are governed by USP <71> and USP <85>. Acid-terminated PLGA 50:50 depots of this type typically exhibit mass loss onset between 4 weeks and 6 weeks under in vitro hydrolysis conditions, but the exact onset depends on pore structure, drug loading, and residual NMP content after precipitation.

In resorbable barrier film production, 50:50 DL-PLG is normally cast from a 10–15 wt% solution in dichloromethane or ethyl acetate onto a fluoropolymer release liner or glass plate using a knife coater with a wet gap of 300–800 µm. Drying is performed in two stages: ambient drying at 20–25°C for 12–24 hours followed by vacuum drying at 30–40°C for 24–48 hours to reduce residual solvent. The resulting film thickness is typically 50–200 µm. Because PLGA 50:50 films are inherently brittle at body temperature, 5–15 wt% triethyl citrate or acetyl tributyl citrate is added when elongation at break above 10% is required. Mechanical properties are measured according to ASTM D882-18; films with residual solvent below 600 ppm dichloromethane or 5,000 ppm ethyl acetate are required for implantable devices under ICH Q3C Option 1 or USP <467>. Sterilisation is achieved by aseptic processing or low-dose gamma irradiation only after molecular weight loss is confirmed acceptable by gel permeation chromatography, because PLGA undergoes chain scission under gamma exposure. Degradation testing follows ASTM F1635-16 in phosphate-buffered saline at 37°C; cytotoxicity testing is conducted under ISO 10993-5, and delayed-type hypersensitivity with implantation under ISO 10993-6 for devices intended for surgical placement. The terminal product is a sterile resorbable film or sheet used as a temporary adhesion barrier, guided tissue regeneration membrane, or local drug-eluting matrix. The principal manufacturing defect is solvent blistering when the first-stage drying rate is too high; this defect raises the measured pinhole density and reduces tensile strength disproportionately relative to film thickness.

When Electrospun Meshes Must Retain Fibre Integrity Above 60% Relative Humidity

Electrospinning of PLGA 50:50 from hexafluoroisopropanol (HFIP) or a 7:3 dichloromethane/dimethylformamide mixture produces nonwoven resorbable meshes with fibre diameters from 500 nm to 2,000 nm. The solution is typically prepared at 10–15 wt% polymer, with conductivity adjusted by adding 0.01–0.1 wt% benzyl triethylammonium chloride or a compatible salt when fibre diameter uniformity must be below 10% coefficient of variation. Processing parameters include a feed rate of 0.5–2.0 mL/h, an applied voltage of 15–25 kV, and a collector distance of 12–18 cm. Relative humidity must be maintained below 50% during spinning; above 60% relative humidity, water uptake into the jet leads to surface porosity, bead defects, and reduced fibre diameter consistency. The resulting mesh is annealed at 45–55°C for 12–24 hours under vacuum to remove residual solvent and improve interfibre bonding. Porosity of the terminal scaffold is controlled between 70% and 90% by adjusting drum rotation speed and deposition time. Mechanical testing under ASTM D638-14 or ASTM D882-18 shows tensile strengths commonly in the 1–5 MPa range for highly porous 50:50 PLGA meshes, with elongation at break from 5% to 30% depending on fibre diameter and bonding. For implantable tissue-support applications, the mesh is punched or cut into sheets, double-bagged, and sterilised by ethylene oxide or low-dose gamma irradiation after molecular weight retention is verified. Cytotoxicity is assessed under ISO 10993-5, and sample preparation for leachables follows ISO 10993-12. In vivo degradation is often assessed under ISO 10993-6 for local tissue reaction. Published field data from production-scale electrospinning lines indicates that batch-to-batch fibre diameter variation is more strongly correlated with room humidity and polymer solution age than with voltage fluctuations within the 15–25 kV range.

Braided Suture Coating Uniformity, Capillary Rise, and Polymer Degradation Debris

When braided synthetic absorbable multifilament yarns are dip-coated with a 2–4 wt% PLGA 50:50 solution in ethyl acetate or acetone, the objective is to control capillary rise, reduce intra-operative fraying, and modulate the early hydration profile. The yarn is passed through a filtered polymer solution at a withdrawal speed of 50–200 mm/min, dried at 35–45°C in a heated column, and wound with controlled tension. Coating add-on is typically 0.5–3 wt% relative to the uncoated yarn. Terminal sutures are packaged in dry-sealed foils after vacuum drying to reduce residual solvent below USP <467> limits. Compliance for a sterile absorbable suture includes USP <71> for sterility, USP <85> for bacterial endotoxins, and ISO 10993-6 for local tissue response because the coated yarn is resorbed over an extended implantation period. Mechanical performance of the coated suture is measured by knot pull strength and needle attachment force under the current USP monograph for synthetic absorbable sutures. The main coating defect occurs when solution viscosity drifts upward during a long production run due to solvent evaporation, causing a thicker coating that reduces knot run-down and increases surface tack. Conversely, a coating layer below 0.5 wt% add-on does not fully fill the interstitial spaces between braided filaments, leaving capillary channels that permit rapid wicking of wound exudate. The acid-terminated PLGA coating should not be combined with amine-functionalised yarn coatings or basic surface treatments because free carboxylic acid groups interact with amines, leading to partial ionic crosslinking and a stiffened coating after ethylene oxide sterilisation.